Edwards' aortic valve with resilia tissue shows favorable durability, safety and efficacy outcomes in seven year data

Los angeles , may 7, 2023 /prnewswire/ -- edwards lifesciences (nyse: ew) today announced new data from the commence aortic trial, demonstrating low rates of structural valve deterioration (svd) in bioprosthetic aortic valves with the company's innovative resilia tissue. the data, which represent the longest clinical follow-up for edwards' bioprosthetic surgical aortic valve with resilia tissue with a mean follow-up of 7.7 years, were presented today at the 103rd annual meeting of the american association for thoracic surgery.
EW Ratings Summary
EW Quant Ranking